论文部分内容阅读
Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.Methods: The effects of imatinib mesylate on cell viability in MCF-7 cell line were assessed using MTT assay and IC_(50) value was determined. GAPDH and KAI1/CD82 were selected as reference and target genes, respectively. Quantitative real time PCR technique was applied for investigation of KAI1/CD82 gene expression in human breast cancer MCF-7 cells. Subsequently, the quantity of KAI1 compared to GAPDH gene expressions were analyzed using the formula; 2~(-DDCt).Results: Imatinib was showed to have a dose-dependent inhibitory effect on the viability of MCF-7 cells. CD82/GAPDH gene expression ratios were 1.322 ± 0.030(P > 0.05),2.052 ± 0.200(P < 0.05), 2.151 ± 0.270(P < 0.05) for 10, 20 and 40 mmol/L of imatinib concentrations.Conclusions: Based on the present data, imatinib mesylate might modulate metastasis by up-regulating KAI1/CD82 gene expression in human breast MCF-7 cancer cell line.
Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1 / CD82 gene expression in breast cancer MCF-7 cell line. Methods: The effects of imatinib mesylate on cell viability in MCF-7 cell line were quantitative using MTT assay and IC 50 (50) value was determined. GAPDH and KAI1 / CD82 were selected as reference and target genes, respectively. Quantitative real time PCR technique was applied for investigation of KAI1 / CD82 gene expression in human breast cancer MCF-7 The quantity of KAI1 compared to GAPDH gene expressions were analyzed using the formula; 2 ~ (-DDCt). Results: Imatinib was showed to have a dose-dependent inhibitory effect on the viability of MCF-7 cells. CD82 / GAPDH gene expression ratios were 1.322 ± 0.030 (P> 0.05), 2.052 ± 0.200 (P <0.05), 2.151 ± 0.270 (P <0.05) for 10, 20 and 40 mmol / L of imatinib concentrations. Conclusions: Based on the present data, imatinib mesylate might modulate metastasis by up-regulating KAI1 / CD82 gene expression in human breast MCF-7 cancer cell line.